Fig 2: Correlation analysis of CAP2, SAP97, and ADAM10 protein levels with age and PMI in the post-mortem dorsolateral prefrontal cortex and hippocampus of schizophrenia patients. Analysis of correlation between age and protein levels of CAP2, SAP97, and ADAM10 in the dorsolateral prefrontal cortex of (a,e,i) control subjects (CTRL, n = 20) and (b,f,j) schizophrenia patients (SCZ, n = 20). Correlation analysis between PMI and protein levels of CAP2, SAP97, and ADAM10 in the dorsolateral prefrontal cortex of (c,g,k) control subjects (n = 20) and (d,h,l) schizophrenia patients (n = 20). Analysis of correlation between age and protein levels of CAP2, SAP97, and ADAM10 in the hippocampus of (m,q,u) control subjects (n = 20) and (n,r,v) schizophrenia patients (n = 20). Correlation analysis between PMI and protein levels of CAP2, SAP97, and ADAM10 in the hippocampus of (o,s,w) control subjects (n = 20) and (p,t,x) schizophrenia patients (n = 20).

Fig 3: Correlation analysis of CAP2, DLG1, and ADAM10 mRNA expression with age and PMI in the post-mortem dorsolateral prefrontal cortex and hippocampus of schizophrenia patients. Analysis of correlation between age and mRNA expression of CAP2, DLG1, and ADAM10 in the dorsolateral prefrontal cortex of (a,e,i) control subjects (CTRL, n = 19) and (b,f,j) schizophrenia patients (SCZ, n = 20). Correlation analysis between PMI and mRNA expression of CAP2, DLG1, and ADAM10 in the dorsolateral prefrontal cortex of (c,g,k) control subjects (n = 19) and (d,h,l) schizophrenia patients (n = 20). Analysis of correlation between age and mRNA expression of CAP2, DLG1, and ADAM10 in the hippocampus of (m,q,u) control subjects (CAP2/ADAM10: n = 20; DLG1: n = 19) and (n,r,v) schizophrenia patients (CAP2: n = 20; DLG1: n = 18; ADAM10: n = 19). Correlation analysis between PMI and mRNA expression of CAP2, DLG1, and ADAM10 in the hippocampus of (o,s,w) control subjects (CAP2/ADAM10: n = 20; DLG1: n = 19) and (p,t,x) schizophrenia patients (CAP2: n = 20; DLG1: n = 18; ADAM10: n = 19).

Fig 4: Analysis of protein expression of CAP2, SAP97, and ADAM10 in the post-mortem dorsolateral prefrontal cortex and hippocampus of schizophrenia patients. Quantification of CAP2, SAP97, and ADAM10 protein levels in the total homogenates of post-mortem (a–c) dorsolateral prefrontal cortex (DLPFC) and (e–g) hippocampus of schizophrenic subjects (SCZ, n = 20) and control group (CTRL, n = 20). The variations of CAP2, SAP97, and ADAM10 levels in schizophrenic patients are expressed as a percentage (%) of the control subjects. All markers were normalized to GAPDH for variations in loading and transfer. (d,h) Representative images of immunoblots of CAP2, SAP97, ADAM10 performed in the DLPFC and hippocampus of the control group and schizophrenia patients. Each dot represents values from a single subject. All experiments were analyzed by the Mann–Whitney test.

Fig 5: Colocalization of CAP2, SAP97, and ADAM10 in primary hippocampal neurons. (a) Schematic representation of CAP2, SAP97, and ADAM10 in the glutamatergic synapse. (b) Fluorescence immunocytochemistry of ADAM10 (green), CAP2 (red), and SAP97 (blue) in primary hippocampal neurons. In the last panel (merge), a colocalization image is shown. Scale bar: 5 μm.